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Abstract
Background: Detection of enzyme activity or transgene expression offers potential insight into developmental biology,
disease progression, and potentially personalized medicine. Historically, the lacZ gene encoding the enzyme b-galactosidase
has been the most common reporter gene and many chromogenic and fluorogenic substrates are well established, but
limited to histology or in vitro assays. We now present a novel approach for in vivo detection of b-galactosidase using
optical imaging to detect light emission following administration of the chemiluminescent 1,2-dioxetane substrate Galacto-
Light PlusTM.
Methodology and Principal Findings: B-gal activity was visualized in stably transfected human MCF7-lacZ tumors growing
in mice. LacZ tumors were identified versus contralateral wild type tumors as controls, based on two- to tenfold greater light
emission following direct intra tumoral or intravenous administration of reporter substrate. The 1,2-dioxetane substrate is
commercially available as a kit for microplate-based assays for b-gal detection, and we have adapted it for in vivo
application. Typically, 100 ml substrate mixture was administered intravenously and light emission was detected from the
lacZ tumor immediately with gradual decrease over the next 20 mins. Imaging was also undertaken in transgenic ROSA26
mice following subcutaneous or intravenous injection of substrate mixture.
Conclusion and Significance: Light emission was detectable using standard instrumentation designed for more traditional
bioluminescent imaging. Use of 1,2-dioxetane substrates to detect enzyme activity offers a new paradigm for non-invasive
biochemistry in vivo.
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Introduction
One of the hottest topics is biology today is non-invasive
characterization of in vivo biochemical processes using various
imaging modalities [1,2]. Detection of enzyme activity or
transgene expression in vivo offers potential insight into develop-
mental biology, disease progression, and potentially personalized
medicine. Historically, the lacZ gene encoding the enzyme b-
galactosidase (b-gal) has been the most common reporter gene
used in molecular biology [3,4,5]. Due to its broad spectrum of
activity, many chromogenic and fluorogenic substrates are well
established, but they are generally limited to histology or in vitro
assays [6,7,8,9]. Thus, there is an increasing interest in the
development of non-invasive reporter techniques to assay lacZ
gene expression in vivo.
Several recent studies have reported novel substrates or novel
applications of substrates allowing detection of b-galactosidase in
vivo. Most current approaches have required direct injection of the
substrate into the tissue of interest, e.g., photoacoustic tomography
(PAT) of 4-chloro-3-bromoindole-galactose (X-gal) [10], single
photon emission computed tomography (SPECT) of 5-[I-125]io-
doindol-3-yl-b-D- galactopyranoside ([I-125]IBDG) [11], and
positron emission tomography (PET) of 2-(4-[125I/123I]iodophe-
nyl)ethyl-1-thio-b-D-galactopyranoside, 3-(2’-[F-18]fluoroethoxy)-
2-nitrophenyl-b-D-galactopyranoside or 3-[C-11]methoxy-2-nitro-
phenyl b-D-galactopyranoside [12,13]. A variety of substrates
based on isomers and analogs of 4-fluoro-2-nitrophenyl-b-D-
galactopyranoside [14,15,16], which exhibit
19F NMR chemical
shift change due to b-gal activity has been presented, demonstrat-
ing the ability to differentiate wild type (WT) and stably transfected
lacZ expressing breast and prostate cells [15,17] and human tumor
xenografts growing in mice [18,19]. Perhaps the most elegant
MRI study to date used a galactose-capped gadolinium ligand
(EgadMe) to follow cell lineage in developing tadpoles by
1H MRI
microscopy following direct intracellular injection of substrate
[20]. We have shown the ability to identify lacZ versus WT MCF7
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1H MRI following direct
intratumoral injection of S-GalH [21].
In vivo detection of b-gal activity based on systemic adminis-
tration of reporter molecules has been achieved using a tandem
approach based on bioluminescence of Lugal (6-o-b-galactopyr-
anosyl-luciferin) following intraperitoneal (IP) administration [22].
However, this approach requires doubly transfected cells, whereby
b-gal (lacZ expression) releases luciferin, which becomes a substrate
for luciferase.
1H MRI signal enhancement was observed in
CT26 tumors (wild type versus lacZ) growing in mice following
intravenous (IV) administration of a gadolinium capped ligand
(GD-DOTA-FBG) [23]. The most widely used approach currently
exploits fluorescence to detect a 50 nm shift accompanying b-gal
activated cleavage of DDAOG (7-hydroxy-9H-(1,3-dichloro-9,9-
dimethylacridin-2-one-7-yl) b-D-galactopyranoside) revealing b-
gal activity in stably transfected human tumors in mice following
IV administration [24,25].
It occurred to us that substrates designed for chemiluminescent
imaging (CLI) of enzyme activity using traditional high throughput
plate readers could provide an alternative approach to detect lacZ
gene expression in vivo. Detection of emitted light in vivo may be
considered bioluminescent imaging (BLI), although BLI is often
associated with activity of luciferases. We now demonstrate the use
of exploiting Galacto-Light PlusTM in vivo to detect gene activity
in lacZ transfected MCF7 tumor cells, MCF7-lacZ xenograft
tumors, and transgenic lacZ gene expressing mice.
Results
The Galacto-Light Plus kit includes several components, and
the importance of each was tested in solution with enzyme.
Substrate (3-chloro-5-(5’-chloro-4-methoxyspiro[1,2-dioxetane-
3,2’-tricyclo[3.3.1.13,7]decan]-4-yl)phenyl b-D-galacto pyranoside
(Galacton Plus), Figure 1a), reaction buffer, and accelerant
(EmeraldTM enhancer and diethanolamine in buffer) were tested
with b-galactosidase. A faint glow was detected for enzyme plus
substrate alone with or without the additional individual reaction
and accelerant buffers, but all three together gave substantially
Figure 1. Detection of b-gal activity by chemiluminescent imaging (CLI) using b-gal enzyme and cultured cells. a) The chemical
structure of Galacto-Light PlusTM substrate; b) Differential light emission from wells containing various enzyme + substrate mixtures. Row A: 10 ml
PBS; Row B: b-galactosidase (1 U in 10 ml PBS (pH: 7.2-7.4)); 1: +20 ml PBS; 2: +1 ml Galacto-plus (diluted to 10 ml in PBS)+10 ml PBS; 3: +10 ml reaction
buffer) +10 ml PBS, 4: +10 ml accelerator buffer +10 ml PBS; 5: +1 ml Galacto-plus +10 ml reaction buffer +10 ml accelerator buffer (1:10:10); 6: +2 ml
Galacto-plus +8 ml reaction buffer +10 ml accelerator buffer (1:4:5) (Total volume: 30 ml per well). c) CLI signal intensity for mixtures in (b) d) Varying
numbers of MCF7-WT (upper A&B) and MCF7-lacZ (lower C&D) breast cancer cells in wells (0, 1610
3,5 610
3 ,1610
4,5 610
4,1 610
5,5 610
5,1 610
6 cells,
respectively) imaged using a sensitive CCD camera (exposure time 2 s) following addition of Galacto-Light PlusTM mixture (comprising 10 ml
substrate +10 ml accelerant + buffer with (rows A,B E, F) or without (rows C, D, G, H) added lysis buffer); e) Signal intensities for MCF7-lacZ (&) and -
WT (D) cells in (d), where open symbols indicate inclusion of lysis buffer. Exposure times ranged from 5 s to 120 s to ensure adequate SNR without
overloading.
doi:10.1371/journal.pone.0012024.g001
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accelerant gave the strongest signal (Figure 1b and c). The mixture
was applied to various concentrations of MCF7-WT and –lacZ
cells (Figure 1d and e). Light emission was found to increase with
increasing cell numbers, particularly below 50,000 cells, though
above this tended to plateau. Light detected from the WT cells was
about 10,000 fold less intense. Addition of lysis buffer to cells
increased the emitted light by a factor of about 10 for the lacZ cells,
but had less effect on WT cells (less than two-fold) (Figure 1e).
Maximum light emission was found at about 540 nm for a reaction
mixture in solution and 530 nm when determined in minced tissue
(Figure S1).
Direct injection of Galacto-Light Plus mixture (30 ml) intratu-
morally (IT) gave a strong signal in MCF7-lacZ tumors easily
detectable in 10 s and much less signal in WT tumors (Figure 2a).
Typical integrated signal for lacZ tumor was 4.0610
5 photons/sec,
whereas a similarly sized contralateral WT tumor gave 7.1610
4
photons/sec, providing over 7-fold contrast, while skin on the back
gave about 1.5610
4 photons/sec and background noise was only
7x10
3 photons/sec. Administration of a 50 ml mixture (30 ml
substrate + 10 ml accelerant + 10 ml reaction buffer) gave a much
higher relative signal (average 10.6 for three tumor pairs) than an
alternate mixture (20:5:5 ml), which gave average 2.5). In general,
the relative signal for lacZ versus WT tumor was found to be
superior for longer signal acquisition times. A dynamic signal
intensity curve showed decrease after 3 mins reaching about 50%
after 15 mins (Figure 2b). Following IV injection MCF7-lacZ
tumor showed signal (SNR 8.6), though it was somewhat less
intense than following IT injection. Nonetheless, it was signifi-
cantly more intense than for WT with a contrast of about five-fold
(Figure 2c). In a separate animal, dynamic variation in emitted
light was assessed over a period of 15 mins following IV injection
(Figure 2d). Intense signal was observed from the lacZ tumor with
about two-fold less signal from the control WT tumor and a
further two-fold less signal from a region of skin on the foreback. A
rapid decline in signal was observed at each location with a half-
Figure 2. Imaging b-gal activity in vivo.a ) Galacto-Light PlusTM substrate mixture (50 ml) was injected intratumorally (IT) into WT and lacZ tumors
respectively, revealing the lacZ tumor based on light emission with a 10 s exposure time. b) Signal dynamics for regions of interest in (a): lacZ-tumor
(blue), WT tumor (red) and upper back (green). c) Optical following IV injection of Galacto-Light PlusTM mixture (100 ml) with 60 s exposure time
(relative light emission 5.5 fold higher for lacZ vs. WT tumor). d) Light emission dynamics for a second tumor-bearing mouse treated as in c. Curves
show signal for specific regions of interest (inset) with highest signal from the lacZ tumor (blue curve), then contralateral WT tumor (red) and lowest
for skin on the upper back (green) each of which decreased with half-life of about 2 mins. Corresponding histology and b-gal expression profiles are
shown in Figure S2.
doi:10.1371/journal.pone.0012024.g002
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H&E staining together with traditional colorimetric assay and
Western blot of tissues confirmed b-gal activity in the MCF7-lacZ
tumors and about 10-fold less in WT tumors (Figure S2).
Following IV injection of Galacto-Light PlusTM mixtures into
129S-Gt (ROSA)26Sor/J mice light emission was observed
extensively throughout the body (Figure 3), though with somewhat
lower intensity than for MCF7-lacZ tumor consistent with the
lower b-gal activity (Figure S2 vs. S4). As an alternate strategy the
substrate was administered subcutaneously (SC) on the back of the
mouse, which generated very local, albeit far more intense signal,
which showed maximum intensity after 5 mins and decreased over
the following 30 mins (Figure S3). b-gal activity was also
demonstrated in excised tissues by direct application of the
mixture and expression was confirmed by X-gal staining of tissue
surface (Figure S4).
Discussion
We have demonstrated the ability to detect b-gal activity non-
invasively using optical imaging in vivo following administration
of Galacto-Light Plus
TM. BLI was successful in identifying lacZ
versus WT tumors following either direct intratumoral or systemic
intravenous administration of the chemiluminescent substrate
together with reaction buffer, and accelerant. BLI also showed
extensive light emission corresponding to b-gal expression
throughout the body of black furry 129S-Gt(ROSA)26Sor/J mice
following IV administration.
The value of any new technology must be placed in the context
of existing methods or alternate approaches. Optical imaging is
receiving much attention with dramatic innovations in reporter
agents, applications and methods. New fluorescent materials
reveal tumor locations and potentially surgical margins [26],
dynamic bioluminescence reveals efficacy of vascular disrupting
agents [27] and radionuclides may be detected by optical imaging
[28]. Several crucial strengths are immediately apparent for BLI of
chemiluminescent substrate. Intra venous administration of
substrates avoids the constraints/requirements of knowing a priori
where the expression will be observed, which confounds many
existing in vivo imaging approaches to b-gal activity based on direct
intra tumor injection of substrate. This potentially allows
observation of deeper tumors without the need for needle access
and potential tissue damage due to direct needle insertion into the
tissue. Light emission avoids the background auto fluorescence,
which handicaps fluorescent reporter molecule strategies. The
commercial Galacto-Light Plus kit is designed for plate reader
assays and includes four components: substrate, reaction buffer,
accelerant buffer, and lysis buffer. Including all components
provided greater light emission presumably because cell lysis
releases intra cellular b-gal facilitating better enzyme substrate
interaction. However, omitting the lysis buffer appears more
satisfactory, particularly, for longitudinal studies in vivo and we
Figure 3. Imaging b-gal activity in transgenic 129S-Gt (ROSA) 26Sor/J mice mouse. Following IV injection of Galacto-Light Plus mixture
(200 ml) light emission was observed with 60 s exposure time over 20 mins, with intense signal at point of injection in tail and time dependant varying
signal from central organs (frontal view). Graph shows variation in signal intensity in tail near point of injection (blue) and separately for the mouse
body (red).
doi:10.1371/journal.pone.0012024.g003
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administration of the remaining mixture to mice.
Tumors expressing b-gal were detected, and extensive tissue
radiance was observed in ROSA26 mice following IV adminis-
tration of the substrate mixture. Direct injection into lacZ tumors
gave even higher light emission, but SC injection in ROSA26 mice
showed local light emission only, which appears quite different
from bioluminescence (BLI) detection of luciferase expression.
Others have shown that luciferin crosses physiological barriers (e.g.,
blood-brain and maternal-fetal [29]) and several groups have
shown effective BLI following subcutaneous (SC), intraperitoneal
(IP), intravenous (IV), or direct tissue injection of luciferin
[30,31,32]. Unlike traditional luciferase-based BLI, signal intensity
tended to decline quite rapidly after administering substrate,
though light emission continued for many minutes. Selective
detection was confirmed in excised tissues by in situ imaging and
histology (Figures S2 and S4).
In comparison to NMR or nuclear imaging techniques, optical
imaging is limited due to tissue light absorption and scattering.
Maximum light emission was measured around 540 nm both in
solution and minced b-gal expressing tumor tissue (Figure S1).
This is a slightly shorter wavelength than the emission reported for
the action of firefly luciferase on luciferin [33]. We note a major
goal of bioluminescent and fluorescent imaging is development of
longer wavelength emissions, and this may be feasible using
wavelength shifters developed for CLI. Others have recently
reported use of chemiluminescent substrates for in vivo imaging of
mice, notably detection of myeloperoxidase based on IV infusion
of luminol [34] and hydrogen peroxide based on peroxalate
nanoparticles [35].
Here, we have demonstrated the ability to detect b-gal activity,
but we note that other chemiluminescence enzyme detection kits
are available and expect that alkaline phosphatase and neuramin-
idase detection could also be effective in vivo. We do note that the
current reagents have been designed for well plate readers
optimized in the blue-green visible range, whereas red to near
infrared would be optimal for in vivo imaging and they could likely
be optimized for in vivo applications. Importantly, use of
chemiluminescent reporter agents adds a new approach to the
armamentarium of the pre-clinical imaging scientist and will
provide new opportunities for in vivo biochemistry, molecular
biology, and therapy.
Materials and Methods
Cells
MCF7 wild type and stably transfected lacZ cell line: E.coli lacZ
gene (from pSV-b-gal vector, Promega, Madison, WI) was inserted
into high expression human cytomegalovirus (CMV) immediate-
early enhancer/promoter vector phCMV (Gene Therapy Systems,
San Diego, CA) giving a recombinant vector phCMV/lacZ, which
was used to transfect human MCF7 wild type breast cancer cell
(ATCC, Manassas, VA) using GenePORTER2 (Gene Therapy
Systems, Genlantis, Inc., San Diego, CA), as described in detail
previously
18. The highest b-gal expressing colony was selected
using G418 (1000 mg/ml) and G418 (200 mg/ml) was included for
routine culture.
Imaging
Optical imaging was performed with a Caliper Xenogen IVISH
Spectrum and images were analyzed using Living Image 3.1
software (Caliper Life Sciences, Hopkinton, MA). Beta-galactosi-
dase (Sigma, St. Louis, MO Cat #G2513-3KU: 1U) was
evaluated with Galacto-Light PlusTM (Tropix, Bedford, MA)
substrate in various solution combinations. The Galacto-Light
PlusTM commercial kit includes four components: Galacton
substrate (3-chloro-5-(5’-chloro-4-methoxyspiro[1,2-dioxetane-
3,2’-tricyclo[3.3.1.13,7]decan]-4-yl)phenyl b-D-Galactopyranoside
(Galacton Plus, T2118), Figure 1a), accelerant (diethanolamine in
buffer containing EmeraldTM enhancer, T2081), reaction buffer
(T2070), and lysis buffer. MCF7-WT and MCF7-lacZ cells (1x10
3
to 1X10
6 cells in 100 ml PBS) were placed in wells in a black clear
bottom 96 well plate (Corning Company, Corning, NY) and 10 ml
of various Galacton mixtures were added with or without the lysis
buffer. Images were acquired in 5 to 120 s.
In vivo imaging
Investigations were approved by the UT Southwestern
Institutional Animal Care and Use Committee under APN
#0464-07-32. MCF7-WT and -lacZ cells (1X10
6) were implanted
SC respectively in the left or right flanks of six female nude mice
[19]. When tumors reached about 5 mm diameter, Galacto-Light
Plus mixture was injected intravenously (100 ml) or intratumorally
(50 ml comprising 30 ml substrate +10 ml accelerant +10 ml
reaction buffer or 30 ml (20:5:50). Similarly, four 129S-Gt
(ROSA)26Sor/J mice (The Jackson Laboratory, Bar Harbor,
ME) were injected SC (with 25 ml mixture) or IV (100 ml or 200 ml
mixture). The anesthetized (isoflurane (1.5%) in oxygen at 1.5
dm
3/min) nude mice bearing MCF7-WT and –lacZ tumors and
ROSA26 mice were observed using the IVISH Spectrum. Images
were acquired up to 180 mins after injection including dorsal and
frontal views with various exposure times.
Ex vivo imaging and X-gal staining
Tumors and organs were excised from mice after in vivo imaging
and 30 ml Galacto-Light plus mixture was added dropwise onto
the tissues. Imaging was performed immediately using the IVIS
Spectrum with 30 s exposures. Organs were also stained with X-
gal solution (1 mg/ml, Research Products International Corp., Mt.
Prospect, IL) for 8 hrs and photographed.
Histology
Tumors were excised after imaging and embedded in Tissue-
Tek OCT (Miles Laboratory, Elkhart, IN) and frozen in liquid
nitrogen. Cryostat sections were collected on gelatin-coated glass
slides, and 8 mm sections stained with nuclear fast red (Sigma) and
1 mg/ml X-gal solution and with H & E (Sigma) individually.
b-gal Assay
The b-gal activity of tumor cells and tissues in mice was
measured using the b-gal assay kit (Promega) with yellow o-
nitrophenyl b-D-galactopyranoside (ONPG). The extracted pro-
tein was quantified by a protein assay (Bio-Rad, Hercules, CA,
USA) based on the Bradford method [36]. The enzyme activity is
expressed as units/mg protein, where one unit corresponds to the
hydrolysis of 1.0 mmol ONPG/min.
Western blot
Protein was extracted from MCF7-WT and –lacZ tumors and
other normal organs, and quantified using the Bradford method.
Each well was loaded with 30 mg protein, separated by 10% SDS-
PAGE (Nu-PAGE), and transferred to a polyvinylidene fluoride
(PVDF) membrane. Primary monoclonal anti-b-gal antibody
(Promega) and anti-actin antibody (Sigma) were used as probes
at a dilution of 1:5000, and reacting protein was detected using a
horseradish peroxidase-conjugated secondary antibody and ECL
detection (Amersham, Piscataway, NJ, USA).
Imaging b-Gal Activity In Vivo
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Figure S1 Emission spectrum for Galacto-Light PlusTM
reaction mixture with b-gal. A mixture of substrate (0.5 ml
Galacto-Light Plus), accelerant buffer (5 ml) and reaction buffer
(4.5 ml) was observed after addition of b-gal enzyme (2 U b-gal in
10 ml PBS) with various emission filters from 500 nm to 840 nm.
Inset shows similar spectrum obtained when minced MCF7-lacZ
tumor tissue was used in place of enzyme.
Found at: doi:10.1371/journal.pone.0012024.s001 (0.54 MB TIF)
Figure S2 Verification of b-gal activity. a) Upper row sections
from MCF7-lacZ tumor; Lower row from and MCF7-WT; (left)
detection of b-gal based on X-gal staining and nuclear fast and
(right) H&E staining. b) b-gal activity in tissues of mouse with
MCF7-lacZ and -WT tumors determined using colorimetric assay.
c) Protein expression based on Western blot confirming high
activity of b-gal in lacZ tumor with about 10% background in
MCF7-WT.
Found at: doi:10.1371/journal.pone.0012024.s002 (1.22 MB TIF)
Figure S3 Imaging b-gal activity in transgenic 129S-Gt
(ROSA)26Sor/J mouse following SC injection of substrate.
Following SC injection of Galacto-Light Plus reaction mixture
(10 ml) highly localized light emission was observed from the
region of injection. The time dependent signal intensity curve
shows maximum light emission after about 5 mins with decay over
the next 30 mins. Signal was much more intense than following IV
injection.
Found at: doi:10.1371/journal.pone.0012024.s003 (0.33 MB TIF)
Figure S4 Detection of b-gal activity in organs of transgenic
129S-Gt (ROSA) 26Sor/J mouse by bioluminescence and b-gal
staining. Left: BLI based on Galacto-Light Plus reveals lacZ
expression ex vivo in various organs. Galacto-Light Plus mixture
(25 ml) was injected into the tissue post mortem and detected with
a 60 s exposure time. Right: Tissue surface staining after exposure
to 1 mg/ml X-gal solution at 37uC for 8 hrs. Bottom: b-gal activity
detected in organs using colorimetric assay.
Found at: doi:10.1371/journal.pone.0012024.s004 (0.50 MB TIF)
Acknowledgments
We are grateful to Jason Reneau for expert technical support of the optical
imaging service and Dr. Matthew Lewis for valuable discussions.
Author Contributions
Conceived and designed the experiments: RPM. Performed the experi-
ments: LL. Analyzed the data: LL. Contributed reagents/materials/
analysis tools: RPM. Wrote the paper: RPM.
References
1. Baker M (2010) Whole-animal imaging: The whole picture. Nature 463:
977–980.
2. Weissleder R, Pittet MJ (2008) Imaging in the era of molecular oncology. Nature
452: 580–589.
3. Jacob F, Monod J (1961) Genetic regulatory mechanisms in the synthesis of
proteins. J Mol Biol 3: 318–356.
4. Murakami T, Kobayashi E (2005) Color-engineered rats and luminescent LacZ
imaging: a new platform to visualize biological processes. J Biomed Opt 10:
1–11.
5. Olesen CEM, Yan Y-X, Liu B, Martin D, D’Eon B, et al. (2000) Novel methods
for chemiluminescent detection of reporter enzymes. Methods Enzymol 326:
175–202.
6. Eustice DC, Feldman PA, Colberg-Poley AM, Buckery RM, Neubauer RH
(1991) A sensitive method for the detection of beta-galactosidase in transfected
mammalian cells. Biotechniques 11: 739–740.
7. James AL, Perry JD, Chilvers K, Robson IS, Armstrong L, et al. (2000) Alizarin-
beta-D-galactoside: a new substrate for the detection of bacterial beta-
galactosidase. Letters Appl Microbiol 30: 336–340.
8. Chilvers KF, Perry JD, James AL, Reed RH (2001) Synthesis and evaluation of
novel fluorogenic substrates for the detection of bacterial beta-galactosidase.
J Appl Microbiol 91: 1118–1130.
9. Masuda-Nishimura I, Fukuda S, Sano A, Kasai K, Tatsumi H (2000)
Development of a rapid positive/absent test for coliforms using sensitive
bioluminescence assay. Lett Appl Microbiol 30: 130–135.
10. Li L, Zemp RJ, Lungu G, Stoica G, Wang LV (2007) Photoacoustic imaging of
lacZ gene expression in vivo. J Biomed Opt 12: 020504.
11. Van Dort ME, Lee KC, Hamilton CA, Rehemtulla A, Ross BD (2008)
Radiosynthesis and evaluation of 5-[125I]iodoindol-3-yl-beta-D-galactopyrano-
side as a beta-galactosidase imaging radioligand. Mol Imaging 7: 187–197.
12. Celen S, Cleynhens J, Deroose C, de Groot T, Ibrahimi A, et al. (2009) Synthesis
and biological evaluation of (11)C-labeled beta-galactosyl triazoles as potential
PET tracers for in vivo LacZ reporter gene imaging. Bioorg Med Chem 17:
5117–5125.
13. Lee KH, Byun SS, Choi JH, Paik JY, Choe YS, et al. (2004) Targeting of lacZ
reporter gene expression with radioiodine-labelled phenylethyl-beta- d-thioga-
lactopyranoside. Eur J Nucl Med Mol Imaging 31: 433–438.
14. Cui W, Otten P, Li Y, Koeneman K, Yu J, et al. (2004) A novel NMR approach
to assessing gene transfection: 4-fluoro-2-nitrophenyl-b-D-galactopyranoside as a
prototype reporter molecule for b-galactosidase. Magn Reson Med 51: 616–
620.
15. Kodibagkar VD, Yu J, Liu L, Hetherington HP, Mason RP (2006) Imaging b-
galactosidase activity using
19F chemical shift imaging of LacZ gene-reporter
molecule 2-fluoro-4-nitrophenol-b-D-galactopyranoside. Magn Reson Imaging
24: 959–962.
16. Yu JX, Otten P, Ma Z, Cui W, Liu L, et al. (2004) A Novel NMR Platform for
Detecting Gene Transfection: Synthesis and Evaluation of Fluorinated Phenyl b-
D-Galactosides with Potential Application for Assessing LacZ Gene Expression.
Bioconj Chem 15: 1334–1341.
17. Kodibagkar VD, Yu J, Liu L, Hetherington HP, Mason RP (2006) Imaging
beta-galactosidase activity using
19F chemical shift imaging of LacZ gene-
reporter molecule 2-fluoro-4-nitrophenol-beta-D-galactopyranoside. Magn Re-
son Imaging 24: 959–962.
18. Liu L, Kodibagkar VD, Yu J-X, Mason RP (2007)
19F-NMR detection of lacZ
gene expression via the enzymic hydrolysis of 2-fluoro-4-nitrophenyl b-D-
galactopyranoside in vivo in PC3 prostate tumor xenografts in the mouse.
FASEB J 21: 2014–2019.
19. Yu JX, Kodibagkar VD, Liu L, Mason RP (2008) A
19F NMR Approach using
Reporter Molecule Pairs to Assess b-Galactosidase in Human Xenograft
Tumors in Vivo. NMR Biomed 21: 704–712.
20. Louie AY, Huber MM, Ahrens ET, Rothbacher U, Moats R, et al. (2000) In
vivo visualization of gene expression using magnetic resonance imaging. Nature
Biotechnol 18: 321–325.
21. Cui W, Liu L, Kodibagkar VD, Mason RP (2010) S-GalH, A Novel
1H MRI
Reporter for b-Galactosidase. Magn Reson Med: early view.
22. Wehrman TS, von Degenfeld G, Krutzik PO, Nolan GP, Blau HM (2006)
Luminescent imaging of beta-galactosidase activity in living subjects using
sequential reporter-enzyme luminescence. Nat Methods 3: 295–301.
23. Chang YT, Cheng CM, Su YZ, Lee WT, Hsu JS, et al. (2007) Synthesis and
characterization of a new bioactivated paramagnetic gadolinium(111) complex
[Gd(DOTA-FPG)(H2O)] for tracing gene expression. Bioconjugate Chemistry
18: 1716–1727.
24. Tung CH, Zeng Q, Shah K, Kim DE, Schellingerhout D, et al. (2004) In vivo
imaging of beta-galactosidase activity using far red fluorescent switch. Cancer
Res 64: 1579–1583.
25. Zhang GJ, Chen TB, Connolly B, Lin SA, Hargreaves R, et al. (2009) In vivo
optical imaging of LacZ expression using lacZ transgenic mice. Assay Drug Dev
Technol 7: 391–399.
26. Zhou H, Luby-Phelps K, Mickey BE, Habib AA, Mason RP, et al. (2009)
Dynamic Near-Infrared Optical Imaging of 2-Deoxyglucose Uptake by
Intracranial Glioma of Athymic Mice. PLoS ONE 4: e8051.
27. Zhao D, Richer E, Antich PP, Mason RP (2008) Antivascular effects of
combretastatin A4 phosphate in breast cancer xenograft assessed using dynamic
bioluminescence imaging (BLI) and confirmed by magnetic resonance imaging
(MRI). FASEB J 22: 2445–2451.
28. Liu H, Ren G, Miao Z, Zhang X, Tang X, et al. (2010) Molecular Optical
Imaging with Radioactive Probes. PLoS ONE 5: e9470.
29. Thorne SH, Contag CH (2005) Using in vivo bioluminescence imaging to shed
light on cancer biology. Proc IEEE 93: 750–762.
30. Contero A, Richer E, Gondim A, Mason RP (2009) High-throughput
quantitative bioluminescence imaging for assessing tumor burden. Methods
Mol Biol 574: 37–45.
31. Paroo Z, Bollinger RA, Braasch DA, Richer E, Corey DR, et al. (2004)
Validating bioluminescence imaging as a high-throughput, quantitative modality
for assessing tumor burden. Molecular Imaging 3: 117–124.
32. Inoue Y, Kiryu S, Izawa K, Watanabe M, Tojo A, et al. (2009) Comparison of
subcutaneous and intraperitoneal injection of d-luciferin for in vivo biolumines-
Imaging b-Gal Activity In Vivo
PLoS ONE | www.plosone.org 6 August 2010 | Volume 5 | Issue 8 | e12024cence imaging. European Journal of Nuclear Medicine and Molecular Imaging
36: 771–779.
33. Hui Z, Timothy CD, Olivier C, Flora K, Bradley WR, et al. (2005) Emission
spectra of bioluminescent reporters and interaction with mammalian tissue
determine the sensitivity of detection in vivo. Journal of Biomedical Optics 10:
041210.
34. Gross S, Gammon ST, Moss BL, Rauch D, Harding J, et al. (2009)
Bioluminescence imaging of myeloperoxidase activity in vivo. Nature Medicine
15: 455–461.
35. Lee D, Khaja S, Velasquez-Castano JC, Dasari M, Sun C, et al. (2007) In vivo
imaging of hydrogen peroxide with chemiluminescent nanoparticles. Nat Mater
6: 765–769.
36. Bradford MM (1976) A rapid and sensitive for the quantitation of microgram
quantities of protein utilizing the principle of protein-dye binding. Analyt
Biochem 72: 248–254.
Imaging b-Gal Activity In Vivo
PLoS ONE | www.plosone.org 7 August 2010 | Volume 5 | Issue 8 | e12024